High-yield overview
Mesenchymal Stromal Cells in Orthopaedics
MultipotentMSCs - bone/cartilage/fat
ISCT3-part minimal definition
ParacrineMain in-vivo mechanism
Not standardisedThe key caveat
Stem-cell potency hierarchy
Totipotent
PatternCan form a whole organism incl. placenta (zygote/early blastomeres).
Treatment
Pluripotent
PatternCan form all three germ layers (embryonic stem cells; induced pluripotent stem cells, iPSCs).
Treatment
Multipotent
PatternLimited lineages within a tissue family - e.g. MESENCHYMAL STROMAL CELLS (bone, cartilage, fat) and haematopoietic stem cells.
Treatment
Unipotent
PatternOne cell type (e.g. committed progenitors).
Treatment
Critical Must-Knows
- Stem cells are defined by SELF-RENEWAL and DIFFERENTIATION potential, graded by potency: totipotent -> pluripotent (embryonic/iPSC) -> multipotent (MSCs, haematopoietic) -> unipotent.
- The cells used in orthopaedic regenerative medicine are MESENCHYMAL STROMAL CELLS (MSCs) - MULTIPOTENT adult cells. The ISCT minimal criteria define them by: (1) plastic ADHERENCE; (2) a surface-marker profile (POSITIVE for CD73, CD90, CD105; NEGATIVE for CD45, CD34, CD14/CD11b, CD79a/CD19 and HLA-DR); and (3) TRILINEAGE differentiation into osteoblasts, chondrocytes and adipocytes.
- MSCs can be harvested from BONE MARROW (the classic source), ADIPOSE tissue (abundant, easy), UMBILICAL CORD/Wharton's jelly and other tissues; sources differ in yield and differentiation behaviour.
- Their main IN-VIVO mechanism is now thought to be PARACRINE and IMMUNOMODULATORY (secreting growth factors, cytokines and extracellular vesicles that recruit host cells and modulate inflammation) rather than large-scale ENGRAFTMENT and direct tissue formation.
- Clinical orthopaedic use is mostly via concentrated preparations - BONE MARROW ASPIRATE CONCENTRATE (BMAC) and adipose-derived cells - for cartilage/osteochondral lesions, osteoarthritis, nonunion and osteonecrosis; culture-EXPANDED MSCs face strict REGULATION (classified as advanced-therapy/cell products in most jurisdictions).
- The honest position: evidence is HETEROGENEOUS and largely early-phase, products are NOT standardised, 'stem-cell clinic' marketing often outstrips data, and culture expansion is tightly regulated - so MSC therapy remains promising but, for most indications, investigational.
Clinical Pearls
- “ISCT MSC criteria in three parts: plastic adherence; CD73+/CD90+/CD105+ and CD45-/CD34-/CD14-/CD19-/HLA-DR-; trilineage (osteo/chondro/adipo) differentiation.
- “Modern view: MSCs work mainly by PARACRINE signalling/immunomodulation, not by becoming the new tissue - 'medicinal signalling cells'.
- “Point-of-care BMAC (minimally manipulated) is regulated differently from culture-EXPANDED MSCs (an advanced-therapy medicinal product).
Engraftment vs Paracrine - the Modern Understanding
Old model
MSCs were thought to home to injury, engraft, and directly become large amounts of new bone or cartilage. In practice, long-term engraftment is limited.
Current model
MSCs act largely by paracrine and immunomodulatory signalling - secreting growth factors, cytokines and extracellular vesicles that recruit and activate host cells and dampen inflammation (hence the term "medicinal signalling cells").
Stem-Cell Hierarchy
Self-Renewal + Differentiation
A stem cell has two defining properties: self-renewal (it can divide to make more of itself) and differentiation (it can become specialised cell types). Potency grades this capacity: totipotent (whole organism incl. placenta) -> pluripotent (all three germ layers - embryonic stem cells, and induced pluripotent stem cells (iPSCs) reprogrammed from adult cells) -> multipotent (restricted lineages, e.g. mesenchymal and haematopoietic stem cells) -> unipotent (one lineage). Orthopaedic regenerative medicine works with adult multipotent MSCs, avoiding the ethical and tumorigenicity concerns of embryonic/pluripotent cells.
What Is an MSC? (ISCT Criteria)
The Three-Part Definition
Because "MSC" had been used loosely, the International Society for Cellular Therapy (ISCT) set minimal criteria for a multipotent mesenchymal stromal cell:
- Plastic adherence in standard culture.
- Surface marker profile - POSITIVE for CD73, CD90, CD105; and NEGATIVE for the haematopoietic/endothelial markers CD45, CD34, CD14 (or CD11b), CD79a (or CD19) and HLA-DR.
- Trilineage differentiation in vitro into osteoblasts, chondrocytes and adipocytes.
Sources & Mechanism of Action
- Bone marrow (BM-MSCs) - the classic source (iliac crest aspirate); well-characterised but MSCs are a small fraction of marrow cells.
- Adipose tissue (AD-MSCs) - abundant and easily harvested by lipoaspiration; high yield.
- Umbilical cord / Wharton's jelly and perinatal tissues - young, proliferative cells; a potential "off-the-shelf" allogeneic source, though differentiation is less consistent than BM-MSCs.
- Others: synovium, periosteum, dental pulp, muscle.
Clinical Applications & Caveats
| 0 | 1 | 2 |
|---|---|---|
| Cartilage / osteochondral lesions | BMAC, AD-MSCs (+/- scaffold) | Promising, mostly early-phase/heterogeneous |
| Knee osteoarthritis | BMAC, adipose-derived | Symptomatic benefit in some trials; not standardised |
| Nonunion / bone defects | BMAC, MSC + graft/scaffold | Adjunct; supportive but variable evidence |
| Osteonecrosis (early femoral head) | Core decompression + BMAC | Some benefit in early (pre-collapse) disease |
| Tendon/ligament, spine fusion | MSC-based | Investigational |
Regulation & The Honest Caveat
A crucial distinction is minimal manipulation versus culture expansion. Point-of-care BMAC (concentrated, same-procedure, minimally manipulated) is regulated more permissively, whereas culture-EXPANDED MSCs are classified as advanced-therapy medicinal products / cell-therapy products and are tightly regulated (e.g. by the FDA and EMA). The overall evidence is heterogeneous and largely early-phase, products and dosing are not standardised, and direct-to-consumer "stem-cell clinics" frequently make claims that outstrip the evidence (with safety concerns). The mature position is cautious, evidence-guided use with honest counselling about the investigational status of most indications.
Evidence & Key Studies
Evidence
Bone and cartilage regeneration with the use of umbilical cord mesenchymal stem cells
Klontzas ME, Kenanidis EI, Heliotis M, Tsiridis E, Mantalaris A • Expert Opinion on Biological Therapy (2015)
Key Findings:
- MSCs can be isolated from umbilical cord (Wharton's jelly, perivascular tissue, blood) and share phenotypic features with bone-marrow-derived MSCs.
- Their osteogenic and chondrogenic differentiation is less consistent than that of bone-marrow MSCs across studies.
- Further work with scaffolds, growth factors and culture technology is needed before they can replace BM-MSCs clinically - illustrating that source matters and standardisation is lacking.
Evidence
The immune microenvironment in cartilage injury and repair
Li M, Yin H, Yan Z, et al. • Acta Biomaterialia (2021)
Key Findings:
- The inflammatory microenvironment after cartilage injury drives chondrocyte death/hypertrophy and matrix breakdown, and progression to osteoarthritis.
- In an inflammatory milieu MSCs undergo aberrant differentiation and chondrocytes dedifferentiate to fibroblast-like cells, yielding mechanically poor fibrocartilage.
- Successful cartilage regeneration requires managing the joint inflammatory/immune microenvironment - underscoring the immunomodulatory rather than purely structural role of cell therapy.
Evidence Attribution
According to PubMed, the source-dependent differentiation and the influence of the inflammatory microenvironment on MSC behaviour come from the cited reviews. The ISCT minimal criteria (plastic adherence; CD73/CD90/CD105 positive, CD45/CD34/CD14/CD19/HLA-DR negative; trilineage differentiation) are the internationally accepted definitional standard for MSCs.
Clinical Decision Scenarios
Practise clinical reasoning and management decisions out loud
Viva scenarioStandard
Clinical prompt
“What is a mesenchymal stromal cell, how is it defined, and how does it differ from a pluripotent stem cell?”
Practical approach
A mesenchymal stromal cell, or MSC, is a multipotent adult cell with self-renewal capacity that can differentiate within the connective-tissue family. It is defined by the International Society for Cellular Therapy minimal criteria, which have three parts: first, the cells must be plastic-adherent in standard culture; second, they must have the right surface-marker profile - positive for CD73, CD90 and CD105, and negative for the haematopoietic and endothelial markers CD45, CD34, CD14 or CD11b, CD79a or CD19, and HLA-DR; and third, they must show trilineage differentiation in vitro into osteoblasts, chondrocytes and adipocytes. This distinguishes MSCs from pluripotent stem cells - embryonic stem cells or induced pluripotent stem cells - which can form cells of all three germ layers and, being far more potent, carry teratoma/tumorigenicity and ethical concerns. MSCs are only multipotent and restricted to mesenchymal lineages, which is part of why they are the practical choice for orthopaedic regenerative medicine.
Key clinical points
MSC = multipotent adult cell, mesenchymal lineages
ISCT: plastic adherence; CD73/CD90/CD105+ and CD45/CD34/CD14/CD19/HLA-DR-; trilineage differentiation
Pluripotent (ESC/iPSC) = all germ layers, higher potency, tumorigenicity/ethical concerns
MSCs preferred clinically (multipotent, adult, fewer concerns)
Common pitfalls
Reciting markers incompletely (need the positive AND negative panels)
Calling MSCs pluripotent (they are multipotent)
Omitting trilineage differentiation from the definition
Further questions
“Name the trilineage outputs - osteoblast, chondrocyte, adipocyte”
“Which markers are negative? - CD45, CD34, CD14/CD11b, CD79a/CD19, HLA-DR”
Viva scenarioStandard
Clinical prompt
“A patient asks for a 'stem-cell injection' for knee osteoarthritis. How do MSCs actually work, what would you offer, and what caveats would you give?”
Practical approach
I would explain that the cells used are mesenchymal stromal cells, and that the modern understanding is that they work mainly by paracrine and immunomodulatory signalling - secreting growth factors, cytokines and extracellular vesicles that recruit the patient's own repair cells, promote blood-vessel formation and dampen inflammation - rather than by engrafting and turning into large amounts of new cartilage; they are sometimes called medicinal signalling cells. In practice, what is offered orthopaedically is usually a concentrated, minimally manipulated preparation such as bone marrow aspirate concentrate or adipose-derived cells, given at the point of care; culture-expanded MSCs are classified as advanced-therapy medicinal products and are tightly regulated. The caveats are important: the evidence is heterogeneous and largely early-phase, products and dosing are not standardised, and direct-to-consumer stem-cell clinics often make claims that outstrip the data and carry safety and cost concerns. I would counsel honestly that for most indications this remains investigational, set realistic expectations, and prefer evidence-guided options.
Key clinical points
Mechanism is mainly paracrine/immunomodulatory ('medicinal signalling cells'), not engraftment
Orthopaedic use is mostly minimally-manipulated BMAC/adipose cells
Culture-expanded MSCs = advanced-therapy product, tightly regulated
Evidence heterogeneous/early-phase; counsel honestly; beware unregulated clinics
Common pitfalls
Claiming MSCs regrow cartilage by becoming chondrocytes en masse
Ignoring the regulatory difference between BMAC and culture-expanded MSCs
Overselling unproven indications
Further questions
“What is BMAC? - Bone marrow aspirate concentrate (minimally manipulated, point-of-care)”
“Where is the evidence relatively better? - Early (pre-collapse) osteonecrosis with core decompression; some cartilage/OA trials”
Mnemonics & Memory Aids
Mnemonic
MSC-79
M
Multipotent, plastic-adherent (Mesenchymal)
S
Surface positive: CD73, CD90, CD105 (Stay positive)
C
CD45/CD34/CD14/CD19/HLA-DR negative (Clear of haematopoietic)
7-9
Trilineage: osteoblast, chondrocyte, adipocyte (the functional test)
Hook:MSC = adherent, CD73/90/105 positive, haematopoietic-marker negative, trilineage capable.
Mnemonic
SIGNAL
S
Secrete growth factors/exosomes (paracrine)
I
Immunomodulation (anti-inflammatory)
G
Growth-factor recruitment of host cells
N
Not mainly engraftment (limited direct tissue formation)
A
Angiogenesis promotion
L
'medicinaL signalling cells' - the modern view
Hook:MSCs SIGNAL more than they build - paracrine and immunomodulatory, not bulk engraftment.
Exam day cheat sheet
Stem Cells & MSCs - Exam Day Cheat Sheet
Hierarchy
- Toti- -> pluri- (ESC/iPSC) -> multi- (MSC, haematopoietic) -> unipotent
- Stem cell = self-renewal + differentiation
- Orthopaedics uses adult multipotent MSCs
ISCT MSC definition
- Plastic adherence
- CD73+/CD90+/CD105+; CD45-/CD34-/CD14(11b)-/CD79a(19)-/HLA-DR-
- Trilineage: osteoblast, chondrocyte, adipocyte
Sources & mechanism
- Bone marrow (classic), adipose (abundant), umbilical cord/Wharton's jelly
- Mechanism mainly paracrine/immunomodulatory ('medicinal signalling cells')
- Limited long-term engraftment
Clinical & caveats
- BMAC/adipose for cartilage/OA/nonunion/early osteonecrosis (with core decompression)
- Minimally-manipulated (BMAC) vs culture-expanded (advanced-therapy, regulated)
- Evidence heterogeneous/early-phase; not standardised; beware unregulated clinics